Isoprostanes as a tool to investigate oxidative stress in scleroderma spectrum disorders - Advantages and limitations [11]

Rheumatology

Volumn 45, Issue 7, 2006, Pages 922-923

  Cracowski, Jean Luc ^a,b  

^a EA 3745   (France)

^b GRENOBLE UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; ISOPROSTANE DERIVATIVE; LIPID;

BLOOD LEVEL; BLOOD VESSEL INJURY; CAPILLAROSCOPY; HUMAN; HYPEREMIA; KIDNEY FAILURE; LETTER; LIPID PEROXIDATION; LUNG DISEASE; OXIDATIVE STRESS; PRIORITY JOURNAL; RAYNAUD PHENOMENON; SCLERODERMA; SYSTEMIC SCLEROSIS; URINE LEVEL;

BIOLOGICAL MARKERS; BLOOD SPECIMEN COLLECTION; HUMANS; ISOPROSTANES; OXIDATIVE STRESS; SCLERODERMA, SYSTEMIC;

EID: 33745608464     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kel139     Document Type: Letter

References (14)

1. LeRoy EC, Medsger TA, Jr. Criteria for the classification of early systemic sclerosis. J Rheumatol 2001;28:1573-6.
2. Morrow JD, Hill KE, Burk RF et al. A series of prostaglandin F2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism. Proc Natl Acad Sci USA 1990; 87:9383-7.
3. Cracowski JL. Isoprostanes: An emerging role in vascular physiology and disease?. Chem Phys Lipids 2004;128:75-83.
4. Roberts LJ, Morrow JD. Measurement of F2-isoprostanes as an index of oxidative stress in vivo. Free Radic Biol Med 2000;28:505-13.
5. Cracowski JL, Durand T, Bessard G. Isoprostanes as a biomarker of lipid peroxidation in humans: Physiology, pharmacology and clinical implications. Trends Pharmacol Sci 2002;23:360-6.
6. Stein CM, Tanner SB, Awad JA, Roberts LJ, Morrow JD. Evidence of free radical-mediated injury (isoprostane overproduction) in scleroderma. Arthritis Rheum 1996;39:1146-50.
7. Cracowski JL, Marpeau C, Carpentier PH et al. Enhanced in vivo lipid peroxidation in scleroderma spectrum disorders. Arthritis Rheum 2001;44:1143-8.
8. Cracowski JL, Carpentier PH, Imbert B et al. Increased urinary F2-isoprostanes in systemic sclerosis, but not in primary Raynaud's phenomenon: Effect of cold exposure. Arthritis Rheum 2002;46:1319-23.
9. Volpe A, Biasi D, Caramaschi P et al. Levels of F2-isoprostanes in systemic sclerosis: Correlation with clinical features. Rheumatology 2006;45:314-20.
10. Cracowski JL, Kom GD, Salvat-Melis M et al. Post occlusive reactive hyperemia inversely correlates to urinary 15-F2t-isoprostane levels in systemic sclerosis. Free Rad Biol Med 2006; in press.
11. Ogawa F, Shimizu K, Muroi E et al. Serum levels of 8-isoprostane, a marker of oxidative stress, are elevated in patients with systemic sclerosis. Rheumatology 2006 [Epub ahead of print].
12. Roberts J, 2nd, Durand T. Special issue on isoprostanes. Preface. Chem Phys Lipids 2004;128:1-2.
13. Chiabrando C, Valagussa A, Rivalta C et al. Identification and measurement of endogenous beta-oxidation metabolites of 8-epi-prostaglandin F2α Biol Chem 1999;274:1313-9.
14. Roberts II LJ, Moore KP, Zachert WE, Oates JA, Morrow JD. Identification of the major urinary metabolite of the F2-isoprostane 8-iso-prostaglandin F2α humans. J Biol Chem 1996;271:20617-20.